Journal: Nature
Article Title: Engineered CD47 protects T cells for enhanced antitumour immunity.
doi: 10.1038/s41586-024-07443-8
Figure Lengend Snippet: Fig. 4 | An engineered variant of CD47 retains binding to SIRPα, but no longer binds to anti-CD47 antibodies. a, Consensus mutations identified in yeast sequenced after sorts 4, 5 and 6. Frequencies of identified mutations out of n = 13, 16 and 12 sequenced clones for sorts 4, 5 and 6, respectively. b, Normalized binding of B6H12, CV-1, human SIRPα and mouse SIRPα to yeast-displayed CD47 WT, CD47(A30P) and CD47(Q31P). c, Crystal structures of CD47 (red) binding to SIRPα (dark pink, left) and B6H12 (light blue, right); residues Ala30 (gold) and Gln31 (blue) are indicated by boxes. d, Normalized binding of human SIRPα, B6H12, TJC4 and Hu5F9 to yeast-displayed CD47 WT, CD47(A30P), CD47(Q31P), CD47(A30P/Q31A) and CD47(E29A). e, Normalized binding of B6H12, TJC4, human SIRPα and mouse SIRPα to full-length CD47 WT,
Article Snippet: Yeast surface display vectors A DNA sequence encoding the CD47 Ig-like domain (Gln19–Ser135) was cloned into the pCTCON2 yeast-surface display vector (Addgene) using the NheI and BamHI sites.
Techniques: Variant Assay, Binding Assay, Clone Assay